• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Eisai

CMS will limit coverage of Aduhelm to people in clinical trials

April 8, 2022 By Sean Whooley

The Centers for Medicare & Medicaid Services (CMS) released a national policy regarding coverage for Aduhelm (aducanumab). Controversy has surrounded the Alzheimer’s drug Aduhelm from Biogen (NSDQ:BIIB) and Eisai (TYO:4523) since the FDA’s fast track approval last year. Three members of an FDA advisory committee resigned after the approval. About a week later, nonprofit watchdog group Public Citizen called for high-profile resignations of […]

Filed Under: Business/Financial News, Featured, Food & Drug Administration (FDA), Medicare, Neurological, News Well, Pharmaceutical, Regulatory/Compliance Tagged With: Aduhelm, Alzheimer's, Biogen, Centers for Medicare and Medicaid Services (CMS), Eisai

HHS OIG will review FDA’s approval of Biogen’s aducanumab

August 4, 2021 By Brian Buntz

The HHS Office of Inspector General will review FDA’s accelerated approval pathway following the controversy surrounding the agency’s approval of the Alzheimer’s drug Aduhelm (aducanumab) from Biogen (NSDQ:BIIB) and Eisai (TYO:4523). Among the controversies surrounding the drug’s approval is the use of the accelerated approval pathway, which led the agency to use a surrogate endpoint to approve aducanumab conditionally.  […]

Filed Under: Featured, Pharmaceutical Tagged With: Aducanumab, Aduhelm, Biogen, Eisai, FDA, HHS

Unraveling aducanumab’s impact remains a challenge

June 16, 2021 By Brian Buntz

The FDA’s conditional approval of Biogen’s (NSDQ:BIIB) and Eisai’s (OTCMKTS:ESALY) Alzheimer’s drug aducanumab (Aduhelm) may have been controversial, but the decision will likely have a significant financial impact. There are 6 million people with Alzheimer’s in the U.S. alone, according to Alzheimer’s Association estimates. Approximately half of those patients have mild symptoms, which is the group most likely […]

Filed Under: Featured, Food & Drug Administration (FDA), Imaging, Neurological, Pharmaceutical, Regulatory/Compliance Tagged With: Alzheimer's disease, Biogen, Cardinal Health, Eisai

10 of the best pharma companies to work for

May 26, 2021 By Brian Buntz

The pharmaceutical industry is on the upswing and is poised to have a compound annual growth rate of 13.7% from 2020 to 2027, according to projections from Grand View Research. The industry’s resurgence is a good opportunity for employees in the sector, who frequently enjoy comfortable salaries. To get a sense of which pharmaceutical companies […]

Filed Under: Featured, Pharmaceutical Tagged With: AstraZeneca, Biogen, Eisai, Janssen, Johnson & Johnson, Merck, Moderna, Novartis, Pfizer, Roche, Roche Pharmaceuticals, Sage Therapeutics

Pharma’s top 20 R&D spenders in 2020

May 13, 2021 By Brian Buntz

The past year has been an unprecedented time for the pharmaceutical industry. On the one hand, the pandemic resulted in substantial delays to clinical trials while also forcing sponsors to rethink clinical trial design to protect participants. But on the other hand, the pandemic underscored the importance of the pharma industry in society.  While the […]

Filed Under: Featured, Pharmaceutical, Research & Development Tagged With: AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, H. Lundbeck, Incyte, Janssen, Merck, Novartis, Otsuka Holdings, Pfizer, Regeneron Pharmaceuticals, Roche, Roche Group, Roche Pharmaceuticals, Sumitomo Danippon Pharma, UCB, Vertex Pharmaceuticals

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS